The mechanism of action of GPR17 antagonists in demyelinating diseases, such as Multiple Sclerosis (MS), is primarily achieved through the regulation of oligodendrocyte differentiation and remyelination. This evidence concerns the gene GPR17 and myeloid sarcoma.